Alternatively Spliced Landscape of PPARγ mRNA in Podocytes is Distinct from Adipose Tissue

Claire Bryant, Amy Webb, Alexander S. Banks, Dawn S. Chandler, Rajgopal Govindarajan, Shipra AgrawalbioRxiv 2022 · DOI

TL;DR

This study reveals that kidney podocytes, crucial for filtering blood, express a specific variant of the PPARγ gene (γ1) that differs from the variant (γ2) found predominantly in fat tissue. This difference in gene expression suggests a distinct role for PPARγ in kidney health and opens avenues for developing more targeted therapies for kidney diseases.

What Problem Does This Paper Address?

Podocytes are specialized cells in the kidney's filtering units (glomeruli) that are vital for maintaining kidney function. When podocytes are damaged, it can lead to proteinuria, chronic kidney disease, and ultimately kidney failure. A protein called PPARγ (peroxisome proliferator-activated receptor gamma) has shown promise in protecting podocytes and reducing proteinuria in various studies. However, PPARγ is known to have different forms (isoforms) that arise from alternative splicing of its mRNA. While PPARγ's role in fat metabolism and insulin sensitivity is well-understood, its specific function and the variants involved in kidney podocytes were largely unknown. This paper aims to fill that knowledge gap by investigating which PPARγ mRNA variants are present in podocytes and how they differ from those in adipose tissue, which could explain PPARγ's distinct roles in these different cell types.

Methods

The researchers employed a multi-pronged approach:

  • Variant-Specific PCR: They designed custom primers to specifically amplify different PPARγ mRNA variants. This allowed them to detect and quantify the presence of various spliced forms of PPARγ in human podocytes and compare them to adipose tissue and other rat tissues (kidney, liver, WAT).
  • RNA Isolation and Analysis: Standard molecular biology techniques were used to isolate RNA from cultured podocytes and tissue samples. This RNA was then used for reverse transcription and subsequent PCR to analyze gene expression.
  • Bioinformatic Analysis: They utilized existing datasets (GEO datasets) and a specialized database (PPARgene) to predict PPAR-response elements (PPREs) in the promoter regions of genes. This helped them understand which genes are likely regulated by PPARγ in podocytes and adipocytes.
  • Functional Enrichment Analysis: Tools like clusterProfiler were used to analyze the biological pathways and functions associated with the PPRE-containing genes identified as unique to either podocytes or adipocytes.

Datasets

The study utilized the following datasets:

  • GEO GSE124622: Bulk RNASeq datasets from untreated control differentiated human immortalized podocytes.
  • GEO GSE129153: Bulk RNASeq datasets from untreated control differentiated human adipocytes.
  • PPARgene database: A database of experimentally verified and computationally predicted PPAR target genes.

The study did not introduce new benchmark datasets but rather analyzed existing ones to gain insights into gene regulation.

Key Insights and Ideas

  • Podocyte-Specific PPARγ Isoform: The most striking finding is that human podocytes primarily express the PPARγ γ1 isoform, while the γ2 isoform, which is well-known for its role in adipogenesis, is largely absent. This is a crucial distinction, suggesting that PPARγ's functions in the kidney are mediated by a different molecular machinery than in fat tissue.
  • Differential Gene Regulation: The distinct PPARγ isoforms in podocytes and adipocytes likely lead to different sets of genes being activated or repressed. This explains why PPARγ has seemingly different roles in these tissues – promoting fat storage in adipocytes versus maintaining kidney filtration in podocytes.
  • Therapeutic Potential: The identification of these distinct isoforms and their differential expression opens the door for developing highly specific PPARγ modulators. Such drugs could target the γ1 isoform in podocytes to treat kidney diseases without causing the unwanted side effects associated with targeting the γ2 isoform (like increased adipogenesis).

Key Results

  • Human podocytes express the PPARγ γ1 variant (Var1) and not the γ2 variant (Var2), which is predominantly found in adipose tissue and liver.
  • Other PPARγ splice variants (Var3, Var4, Var11, Var9, tORF4) were detected at very low or undetectable levels in podocytes.
  • A distinct set of PPAR-response element (PPRE)-containing genes were identified in podocytes compared to adipocytes, suggesting cell-specific transcriptional regulation by PPARγ.
  • Functional enrichment analysis revealed that PPRE-containing genes unique to podocytes are involved in cell-cell adhesion and junction formation, crucial for podocyte integrity. In contrast, adipocyte-specific genes were enriched in lipid metabolism and homeostasis pathways.
  • The expression of PPARγ variants encoding γ1 (Var1 and Var4) remained unchanged in podocytes under conditions of injury (PAN-induced) or treatment with a PPARγ agonist (pioglitazone).

Limitations and Future Work

  • In Silico Prediction Limitations: The authors acknowledge that in silico prediction of PPREs has limitations and that species-specific differences in PPRE location and function may exist.
  • Low Expression of Other Variants: The very low expression levels of some PPARγ splice variants in podocytes make their functional characterization challenging.
  • Future Directions: The authors suggest overexpressing these less common variants in podocytes using reporter plasmids to analyze their effects on podocyte physiology, especially under injury conditions. They also propose investigating the presence of these variants in kidney biopsies from patients treated with PPARγ agonists. The ultimate goal is to develop novel selective PPARγ modulators that can differentiate between the γ1 and γ2 isoforms for targeted therapeutic applications in kidney diseases.

Summary updated

Abstract

Abstract Podocytes are highly differentiated epithelial cells, and their structural and functional integrity is compromised in a majority of glomerular and renal diseases, leading to proteinuria, chronic kidney disease, and kidney failure. Traditional agonists (e.g., pioglitazone) and selective modulators (e.g., GQ-16) of peroxisome-proliferator-activated-receptor-γ (PPARγ) reduce proteinuria in animal models of glomerular disease and protect podocytes from injury via PPARγ activation. This indicates a pivotal role for PPARγ in maintaining glomerular function through preservation of podocytes distinct from its well-understood role in driving insulin sensitivity and adipogenesis. While its transcriptional role in activating adipokines and adipogenic genes is well-established in adipose tissue, liver and muscle, understanding of podocyte PPARγ signaling remains limited. We performed a comprehensive analysis of PPARγ mRNA variants due to alternative splicing, in human podocytes and compared with adipose tissue. We found that podocytes express the ubiquitous PPARγ Var 1 (encoding γ1) and not Var2 (encoding γ2), which is mostly restricted to adipose tissue and liver. Additionally, we detected expression at very low level of Var4, and barely detectable levels of other variants, Var3, Var11, VartORF4 and Var9, in podocytes. Furthermore, a distinct podocyte vs adipocyte PPAR-promoter-response-element containing gene expression, enrichment and pathway signature was observed, suggesting differential regulation by podocyte specific PPARγ1 variant, distinct from the adipocyte-specific γ2 variant. In summary, podocytes and glomeruli express several PPARγ variants, including Var1 (γ1) and excluding adipocyte-specific Var2 (γ2), which may have implications in podocyte specific signaling and pathophysiology. This suggests that new selective PPARγ modulators can be potentially developed that will be able to distinguish between the two forms, γ1 and γ2, thus forming a basis of novel targeted therapeutic avenues.
BibTeX
@misc{bryant2022alternatively,
  author = {Claire Bryant and Amy Webb and Alexander S. Banks and Dawn S. Chandler and Rajgopal Govindarajan and Shipra Agrawal},
  title = {{Alternatively Spliced Landscape of PPARγ mRNA in Podocytes is Distinct from Adipose Tissue}},
  year = {2022},
  doi = {10.1101/2022.09.12.507605},
  howpublished = {bioRxiv},
}
Figure